Merck 2008 Annual Report Download - page 114

Download and view the complete annual report

Please find page 114 of the 2008 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 153

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153

Major companies of the Merck Group by region
Direct equity
interest
in %
Sales *
€ million
Profit
after tax *
€ million
Net equity *
€ million Employees
Germany/Europe
Merck KGaA, Darmstadt, Germany Parent company 2,367.8 63.0 4,720.5 9,068
Ares Trading SA, Aubonne, Switzerland 100.00 2,365.5 86.5 222.7 99
Laboratoires Serono SA, Coinsins, Switzerland 100.00 1,444.9 –115.68,628.0 640
Merck Serono S.p.A., Rome, Italy 96.72 1,128.2 67.1 298.9 647
Merck Lipha Santé S.A.S., Lyon, France 100.00 529.2 29.2 58.2 486
Merck Santé S.A.S., Lyon, France 100.00 489.1 99.2 295.9 1,145
Merck Pharma GmbH, Darmstadt, Germany 100.00 404.5 147
Merck Farma y Quimica S.L., Madrid, Spain 100.00 388.8 41.4 132.1 864
Merck Serono UK, West Drayton, United Kingdom 100.00 147.5 12.1 1.7 205
Merck CHC France Group, Lyon, France 100.00 104.2 7.2 44.4 211
Laboratoire Théramex S.A.M., Monaco 99.88 93.2 9.7 20.6 370
Seven Seas Group, Hull, United Kingdom 100.00 81.4 3.8 10.4 340
Merck AG, Zug, Switzerland and Darmstadt, Germany 100.00 74.0 1,761.9 –
North America
EMD Serono US Group, Rockland, MA United States 100.00 689.2 13.1 227.8 810
EMD Chemicals, Inc., Gibbstown, NJ United States 100.00 231.3 4.0 244.6 950
EMD Serono Canada Inc., Mississauga, Canada 100.00 77.6 1.7 14.4 95
Latin America
Merck S.A., Rio de Janeiro, Brazil 100.00 251.2 13.0 52.4 1,132
Merck, S.A. de C.V., Estado de México, Mexico 100.00 174.5 20.3 47.9977
Merck Venezuela Group, Caracas, Venezuela 100.00 106.7 21.2 29.8 276
Ares Trading Uruguay S.A., Montevideo, Uruguay 100.00 93.4 39.6 20.623
Merck S.A., Bogota, Colombia 100.00 69.5 2.8 25.3 577
Merck Quimica Argentina S.A.I.C.,
Buenos Aires, Argentina 100.00 65.5 –2.8 6.0 356
Asia, Africa, Australasia
Korean companies, South Korea 100.00 397.9 69.9 88.6 361
Merck Ltd., Tokyo, Japan 100.00 333.7 28.4 105.7 468
Taiwanese companies, Taiwan 100.00 327.8 30.6 89.6 390
Merck Pharmaceutical (HK) Co., Ltd., Hong Kong, China 100.00 123.13.52.5 37
Merck Ltd., Mumbai, India 51.00 61.2 9.6 72.3 1,072
PT Merck Tbk, Jakarta, Indonesia 86.65 44.7 7.0 21.5 782
* Figures for the entire company unconsolidated, irrespective of the equity interest
A statement of the Merck Group’s equity interests is filed with the electronic Federal Gazette and can be accessed
at www.ebundesanzeiger.de. Major companies of the Merck Group as of December 31, 2008 are presented in the
following table:
72 Income Statement
73 Balance Sheet
74 Segment Reporting
CONSOLIDATED FINANCIAL STATEMENTS OF THE MERCK GROUP
76 Cash Flow Statement
77 Free Cash Flow
77 Statement of Recognized
Income and Expense
78 Statement of Changes
in Net Equity including
Minority Interest
79 Notes
109